Kyowa Kirin Initiated CVC

**Tokyo, Japan, 5 October 2022** -- Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announces today that the company has launched its corporate venture capital (CVC) fund and invested in its first biotech start-up.

In its 2021-2025 Medium Term Business Plan, Kyowa Kirin has committed to “Provide pharmaceuticals for unmet medical needs” as one of its strategic pillars to realize the “Successful creation and delivery of life-changing value,” which is stated in Kyowa Kirin’s vision. As one of the efforts supporting that strategic pillar, Kyowa Kirin has invested in venture capital (VC) funds and focused internal resources to ensure greater access to cutting-edge biotechnologies. Kyowa Kirin initiated its internal CVC function as a way of increasing rapid access to the latest biotechnologies from which the future of drug discovery will emerge.

As its first CVC investment, Kyowa Kirin has invested in Cellarity, Inc., a biotech start-up in the United States, founded by Flagship Pioneering, that is using new technologies to change the way drugs are created. With proactive investments through VC/CVCs like this, Kyowa Kirin will realize its vision for the creation and delivery of life-changing value.

Takeyoshi Yamashita, Ph.D., Managing Executive Officer, Vice President and Head of Strategy Division commented. “We are pleased to make this important progress, as we recognize the need to deliver innovative therapies to patients especially through our new investment arm. We will also continue to accelerate our open innovation activities including CVC investment, that may allow us to combine our in-house R&D capabilities with external resources for enriching our early assets in the future.”

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.